Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $88.1 million.

  • Iovance Biotherapeutics' Cash from Financing Activities rose 10988.7% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.9 million, marking a year-over-year decrease of 3657.87%. This contributed to the annual value of $390.7 million for FY2024, which is 1561.59% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Cash from Financing Activities stood at $88.1 million for Q3 2025, which was up 10988.7% from $13.2 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Cash from Financing Activities' 5-year high stood at $258.2 million during Q1 2023, with a 5-year trough of $962000.0 in Q4 2023.
  • In the last 3 years, Iovance Biotherapeutics' Cash from Financing Activities had a median value of $88.1 million in 2025 and averaged $99.8 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Cash from Financing Activities skyrocketed by 1480975.61% in 2024, and later plummeted by 9134.3% in 2025.
  • Iovance Biotherapeutics' Cash from Financing Activities (Quarter) stood at $962000.0 in 2023, then skyrocketed by 140.02% to $2.3 million in 2024, then soared by 3713.6% to $88.1 million in 2025.
  • Its last three reported values are $88.1 million in Q3 2025, $13.2 million for Q2 2025, and $143.3 million during Q1 2025.